FR11C0002I2 - Poudre permettant d'induire le retrecissement des voies aeriennes et/ou la production de crachat - Google Patents

Poudre permettant d'induire le retrecissement des voies aeriennes et/ou la production de crachat

Info

Publication number
FR11C0002I2
FR11C0002I2 FR11C0002C FR11C0002C FR11C0002I2 FR 11C0002 I2 FR11C0002 I2 FR 11C0002I2 FR 11C0002 C FR11C0002 C FR 11C0002C FR 11C0002 C FR11C0002 C FR 11C0002C FR 11C0002 I2 FR11C0002 I2 FR 11C0002I2
Authority
FR
France
Prior art keywords
pct
person
narrowing
asthma
susceptibility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0002C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sydney West Area Health Service SWAHS
Original Assignee
Sydney West Area Health Service SWAHS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sydney West Area Health Service SWAHS filed Critical Sydney West Area Health Service SWAHS
Publication of FR11C0002I1 publication Critical patent/FR11C0002I1/fr
Application granted granted Critical
Publication of FR11C0002I2 publication Critical patent/FR11C0002I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Seasonings (AREA)
FR11C0002C 1994-02-25 2011-01-21 Poudre permettant d'induire le retrecissement des voies aeriennes et/ou la production de crachat Active FR11C0002I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM4114A AUPM411494A0 (en) 1994-02-25 1994-02-25 Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
PCT/AU1995/000086 WO1995022993A1 (fr) 1994-02-25 1995-02-23 Procede et dispositif permettant d'induire le retrecissement des voies aeriennes et/ou la production de salive

Publications (2)

Publication Number Publication Date
FR11C0002I1 FR11C0002I1 (fr) 2011-01-25
FR11C0002I2 true FR11C0002I2 (fr) 2016-03-25

Family

ID=3778730

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0002C Active FR11C0002I2 (fr) 1994-02-25 2011-01-21 Poudre permettant d'induire le retrecissement des voies aeriennes et/ou la production de crachat

Country Status (15)

Country Link
US (1) US5817028A (fr)
EP (1) EP0748228B8 (fr)
JP (7) JP3979660B2 (fr)
KR (1) KR100385675B1 (fr)
CN (1) CN1075737C (fr)
AT (1) ATE474583T1 (fr)
AU (2) AUPM411494A0 (fr)
CA (1) CA2183471C (fr)
DE (2) DE122011000004I1 (fr)
DK (1) DK0748228T3 (fr)
ES (1) ES2349027T3 (fr)
FR (1) FR11C0002I2 (fr)
NZ (1) NZ281522A (fr)
PT (1) PT748228E (fr)
WO (1) WO1995022993A1 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747002A (en) * 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
DK0902777T4 (da) 1996-04-16 2004-10-11 Takeda Chemical Industries Ltd D-mannitol og dets fremstilling
US6235947B1 (en) * 1997-04-14 2001-05-22 Takeda Chemical Industries, Ltd. D-mannitol and its preparation
US7992572B2 (en) 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
US6634363B1 (en) 1997-04-07 2003-10-21 Broncus Technologies, Inc. Methods of treating lungs having reversible obstructive pulmonary disease
US7027869B2 (en) 1998-01-07 2006-04-11 Asthmatx, Inc. Method for treating an asthma attack
US5881720A (en) * 1997-04-29 1999-03-16 The Procter & Gamble Company Method of delivering halotherapy
US6339075B1 (en) 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
US7921855B2 (en) 1998-01-07 2011-04-12 Asthmatx, Inc. Method for treating an asthma attack
US8181656B2 (en) 1998-06-10 2012-05-22 Asthmatx, Inc. Methods for treating airways
US7198635B2 (en) 2000-10-17 2007-04-03 Asthmatx, Inc. Modification of airways by application of energy
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
JP2002532520A (ja) * 1998-12-22 2002-10-02 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 気道病治療および気道用薬剤送達のための化合物および方法
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
AU772798B2 (en) 1999-04-21 2004-05-06 1355540 Ontario Inc. Formulations for detecting asthma
WO2001062264A2 (fr) * 2000-02-23 2001-08-30 The Procter & Gamble Company Procede d'halotherapie
US8251070B2 (en) 2000-03-27 2012-08-28 Asthmatx, Inc. Methods for treating airways
GB0014898D0 (en) * 2000-06-19 2000-08-09 Innovata Biomed Ltd Delivery system
US7104987B2 (en) 2000-10-17 2006-09-12 Asthmatx, Inc. Control system and process for application of energy to airway walls and other mediums
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
WO2003092654A1 (fr) * 2002-05-02 2003-11-13 President And Fellows Of Harvard College Formulations limitant l'extension d'infections pulmonaires
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
EP2308469A1 (fr) * 2005-05-18 2011-04-13 Pulmatrix, Inc. Formulations pour la modification de propriétés biophysiques des muqueuses
AR062742A1 (es) * 2006-09-07 2008-12-03 Johnson Michael R Hidratacion de la mucosa y depuracion de la mucosa aumentadas por tratamiento con bloquadores de canales de sodio y osmolitos
CA2663041A1 (fr) * 2006-09-07 2008-03-13 Parion Sciences, Inc. Procedes pour ameliorer l'hydratation de muqueuse et la clairance de muqueuse par traitement avec des bloqueurs de canal sodique et des osmolytes
US8714153B2 (en) * 2007-04-16 2014-05-06 Ric Investments, Llc Method for selecting a device adapted to treat disordered breathing
AU2008310734B2 (en) 2007-10-10 2014-06-05 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
JP5611844B2 (ja) 2008-02-26 2014-10-22 パリオン・サイエンシィズ・インコーポレーテッド 多環芳香族ナトリウムチャネル遮断薬
ES2398052T5 (es) 2008-05-09 2021-10-25 Nuvaira Inc Sistemas para tratar un árbol bronquial
RU2577698C2 (ru) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
EP2926757B1 (fr) 2009-10-27 2023-01-25 Nuvaira, Inc. Dispositifs d'administration dotés d'ensembles d'émission d'énergie pouvant être refroidis
MD4039C1 (ro) * 2009-11-05 2010-12-31 Институт Химии Академии Наук Молдовы Microsalină artificială de suprafaţă
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
CN106618731B (zh) 2009-11-11 2020-08-07 努瓦拉公司 用于处理组织和控制狭窄的系统、装置和方法
MD4089C1 (ro) * 2009-11-18 2011-08-31 Институт Химии Академии Наук Молдовы Halocameră artificială de suprafaţă
MD4040C1 (ro) * 2009-12-09 2010-12-31 Институт Химии Академии Наук Молдовы Halocameră artificială de suprafaţă
EP2464346A1 (fr) 2010-08-30 2012-06-20 Pulmatrix, Inc. Méthodes de traitement de la mucoviscidose
JP5877201B2 (ja) 2010-08-30 2016-03-02 パルマトリックス，インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Co Inc CATIONIC DRY POWDER
CN103228273B (zh) 2010-09-29 2017-04-05 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AU2012267938B2 (en) * 2011-06-07 2017-05-04 Parion Sciences, Inc. Methods of treatment
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013003444A1 (fr) 2011-06-27 2013-01-03 Michael Ross Johnson Dipeptide stable d'un point de vue chimique et métabolique caractérisé par une puissante activité inhibitrice sur les canaux sodiques
CA2865972C (fr) 2012-02-29 2022-01-04 Pulmatrix, Inc. Poudres seches pouvant etre inhalees
AU2013267504B2 (en) 2012-05-29 2017-11-02 Parion Sciences, Inc. Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
EP3868321B1 (fr) 2012-06-04 2022-11-16 Boston Scientific Scimed, Inc. Systèmes pour le traitement d'un tissu dans une voie de passage au sein d'un corps
EP2877113B1 (fr) 2012-07-24 2018-07-25 Boston Scientific Scimed, Inc. Électrodes pour traitement de tissu
US9272132B2 (en) 2012-11-02 2016-03-01 Boston Scientific Scimed, Inc. Medical device for treating airways and related methods of use
WO2014071372A1 (fr) 2012-11-05 2014-05-08 Boston Scientific Scimed, Inc. Dispositifs de distribution d'énergie à des lumières corporelles
MX2015007796A (es) 2012-12-17 2015-09-04 Parion Sciences Inc Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales.
NZ709197A (en) 2012-12-17 2020-06-26 Parion Sciences Inc 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
CA2907566C (fr) 2013-04-01 2023-08-22 Pulmatrix, Inc. Poudres seches de tiotropium
EP3708104A1 (fr) 2013-08-09 2020-09-16 Boston Scientific Scimed, Inc. Cathéter expansible et procédés de fabrication et d'utilisation associés
CN104510726A (zh) * 2013-09-27 2015-04-15 张金华 一种用于清洁呼吸道系统的食盐干粉吸入剂
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
KR102288656B1 (ko) 2020-12-02 2021-08-12 순천향대학교 산학협력단 천식 또는 천식 악화 진단용 pcr 키트 및 이를 이용한 천식 또는 천식 악화 진단을 위한 정보의 제공방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623936A (en) * 1979-08-01 1981-03-06 Chest Corp Measuring apparatus of trachea hypersensitivity
US4446862A (en) * 1979-10-30 1984-05-08 Baum Eric A Breath actuated devices for administering powdered medicaments
DE3167567D1 (en) * 1980-06-06 1985-01-17 Fisons Plc Inhalation device for powdered medicaments
ES8206980A1 (es) * 1980-10-30 1982-09-01 Riker Laboratories Inc Un dispositivo para facilitar la inhalacion oral de medica- mentos en forma de polvo
JPS6168418A (ja) * 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd 去痰薬
DE3518665C2 (de) * 1985-05-23 1994-03-17 Hoelter Heinz Holzfilter zum Erzeugen von gereinigter und natürlich duftender Atemluft
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
CA1317194C (fr) * 1989-05-31 1993-05-04 Yves Cloutier Dispositif concu pour certains tests respiratoires, methode d'utilisation et generateur de particules ameliore
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
NL9002706A (nl) * 1990-12-10 1992-07-01 Pharmachemie Bv Inrichting ten gebruike bij het inhaleren van in staafvormige capsules verpakte poedervormige stoffen.
GB9101592D0 (en) * 1991-01-24 1991-03-06 Glaxo Group Ltd Compositions
AU2746292A (en) * 1991-10-30 1993-05-06 Kenneth Roy Hanson Asthma and other allergies cure
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
US5507277A (en) * 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
US5558085A (en) * 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
WO1994017822A1 (fr) * 1993-02-12 1994-08-18 T Cell Sciences, Inc. ADMINISTRATION PULMONAIRE DE RECEPTEUR DE COMPLEMENT SOLUBLE sCR1 ET D'AUTRES PROTEINES D'INHIBITION DU COMPLEMENT
US5497763A (en) * 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
GB9408053D0 (en) * 1994-04-22 1994-06-15 Nat Heart & Lung Inst Pharmaceutical preparation
US5509404A (en) * 1994-07-11 1996-04-23 Aradigm Corporation Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values
US5522385A (en) * 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery

Also Published As

Publication number Publication date
AU682756B2 (en) 1997-10-16
KR100385675B1 (ko) 2003-10-10
JP3979660B2 (ja) 2007-09-19
EP0748228B8 (fr) 2010-08-25
JP2011148840A (ja) 2011-08-04
CA2183471A1 (fr) 1995-08-31
JP2007056040A (ja) 2007-03-08
NZ281522A (en) 1998-09-24
JP2013049708A (ja) 2013-03-14
ATE474583T1 (de) 2010-08-15
ES2349027T3 (es) 2010-12-21
CN1075737C (zh) 2001-12-05
JP2013136564A (ja) 2013-07-11
DE122011000004I1 (de) 2011-05-05
DK0748228T3 (da) 2010-10-11
AU1748295A (en) 1995-09-11
JP2011148839A (ja) 2011-08-04
FR11C0002I1 (fr) 2011-01-25
AUPM411494A0 (en) 1994-03-24
WO1995022993A1 (fr) 1995-08-31
EP0748228A4 (fr) 1999-12-22
CA2183471C (fr) 2008-07-29
EP0748228B1 (fr) 2010-07-21
JPH10501790A (ja) 1998-02-17
JP2007056039A (ja) 2007-03-08
EP0748228A1 (fr) 1996-12-18
CN1142190A (zh) 1997-02-05
US5817028A (en) 1998-10-06
PT748228E (pt) 2010-09-15
DE69536090D1 (de) 2010-09-02

Similar Documents

Publication Publication Date Title
FR11C0002I2 (fr) Poudre permettant d'induire le retrecissement des voies aeriennes et/ou la production de crachat
Fubini et al. Chemical aspects of the toxicity of inhaled mineral dusts
Anderson History of aerosol therapy: liquid nebulization to MDIs to DPIs
Broday et al. Growth and deposition of hygroscopic particulate matter in the human lungs
Castranova et al. Augmentation of pulmonary reactions to quartz inhalation by trace amounts of iron-containing particles.
Sturm Deposition and cellular interaction of cancer‐inducing particles in the human respiratory tract: Theoretical approaches and experimental data
Brand et al. Aerosol bolus dispersion in healthy subjects
Gardner et al. Toxicology of the Lung
Adamis et al. In vitro and in vivo tests for determination of the pathogenicity of quartz, diatomaceous earth, mordenite and clinoptilolite
Lemen Chrysotile asbestos as a cause of mesothelioma: application of the Hill causation model
SCHEUCH et al. An approach to deposition and clearance measurements in human airways
Yao et al. An overlooked route of inhalation exposure to tap water constituents for children and adults: Aerosolized aqueous minerals from ultrasonic humidifiers
Duan et al. Measuring the administered dose of particles on the facial mucosa of a realistic human model
Li et al. Wearing time and respiratory volume affect the filtration efficiency of masks against aerosols at different sizes
CN101466436A (zh) 测定颗粒产生的诊断装置
CN205786347U (zh) 一种甲醛快速定量试剂盒
Chan et al. Regional deposition of nebulized hypodense nonisotonic solutions in the human respiratory tract
Lay et al. Effects of inhaled iron oxide particles on alveolar epithelial permeability in normal subjects
Martonen et al. Comments on recent data for particle deposition in human nasal passages
MY115838A (en) Method and device for the provocation of air passage narrowing and/or the induction of sputum
Polatli et al. Perlite exposure and 4-year change in lung function
Hinds The lung and the environment
Sankhala et al. Factors that affect the lung deposition
Hesbert et al. Interdependence of polymorphonuclear neutrophils and macrophages stained for N-acetyl-β-glucos-aminidase in lavage effluents from toluene diisocyanate-exposed rat lungs
Kilburn Asbestos and other fibers